Akebia Therapeutics (AKBA) investor relations material

Executive summary

• The annual meeting will be held virtually on June 17, 2026, with voting on five key proposals, including director elections, amendments to the certificate of incorporation, executive compensation, vote frequency on compensation, and auditor ratification.

• The board recommends voting for all director nominees, for the amendment to increase authorized shares, for executive compensation, for annual say-on-pay votes, and for ratification of the auditor.

• Forward-looking statements highlight plans for product launches, clinical trials, and pipeline expansion, with risk factors including regulatory, market, and operational uncertainties.

Voting matters and shareholder proposals

• Proposal 1: Elect three Class III directors to serve until 2029.

• Proposal 2: Approve an amendment to increase authorized capital stock from 375M to 525M and common stock from 350M to 500M.

• Proposal 3: Advisory vote on executive compensation (say-on-pay).

• Proposal 4: Advisory vote on frequency of say-on-pay (board recommends annual).

• Proposal 5: Ratify Ernst & Young LLP as independent auditor for 2026.

Board of directors and corporate governance

• The board consists of eight members divided into three classes, with staggered terms.

• Director nominees and continuing directors have extensive industry, financial, and governance experience.

• Board committees (Audit, Compensation, Nominating & Governance, R&D) are composed entirely of independent directors.

• Annual board and committee evaluations are conducted, with feedback used to enhance governance practices.

• The board separates the roles of CEO and Chairperson to reinforce independence.